This review highlights the broad cardiovascular and metabolic benefits of generic valsartan across various conditions including hypertension, heart failure, and diabetes.
May support valsartan preference in hypertension with cardiometabolic risk; leaves open prospective RCTs for practice change.
Angiotensin receptor blockers represent a relevant group of cardiovascular drugs. The results of clinical trials of a generic Valsartan (Valsakor) are reviewed in the paper. Valsartan combines high antihypertensive and organoprotective effects with the low risk of signiicant drug interactions. Due to the favorable metabolic proile valsartan is the drug of choice in hypertension, metabolic syndrome and type 2 diabetes mellitus, and the long-term therapy is associated with the reduction of the risk of new-onset diabetes. Valsartan is effective in primary and secondary prevention of atrial ibrillation, congestive heart failure and chronic renal failure.
No takes yet. Share an insight, caveat, or question.
Максимов et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: